| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Ziprasidone hydrochloride is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity, and is used in the treatment of schizophrenia and bipolar disorder. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01185743 | Schizophrenia ... 展开 >> Diabetes 收起 << | Phase 4 | Completed | - | Austria ... 展开 >> Medical University of Vienna Vienna, Austria, 1090 收起 << |
| NCT00288366 | Schizophrenia ... 展开 >> Schizoaffective Disorder Bipolar Disorder 收起 << | Not Applicable | Completed | - | United States, Tennessee ... 展开 >> Psychiatric Hospital at Vanderbilt Nashville, Tennessee, United States, 37212 收起 << |
| NCT01598324 | - | Terminated(Clinical trial from... 展开 >> which subjects were recruited closed to enrollment) 收起 << | - | United States, Massachusetts ... 展开 >> McLean Hospital - McLean Imaging Center Belmont, Massachusetts, United States, 02478 收起 << | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.23mL 0.45mL 0.22mL |
11.13mL 2.23mL 1.11mL |
22.25mL 4.45mL 2.23mL |
| 参考文献 |
|---|